University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.
Curr Drug Res Rev. 2021;13(3):203-221. doi: 10.2174/2589977513666210315094752.
The novel coronavirus disease 2019 (COVID-19), emerged in Wuhan, China in December 2019 and then spread worldwide rapidly. The records from World Health Organisation (WHO), Centres of Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) backup the fact that no medications have proven to be completely effective for prevention or treatment of SARS-CoV-2. The clinical trials are underway for many repurposed, investigational drugs and vaccine candidates. BioNTech and Pfizer Inc, Moderna, Gamaleya institute and University of Oxford (collaboration with AstraZeneca) announced positive results in the Phase 3 interim analyses of vaccine trials in November 2020. Twelve countries have approved Pfizer- BioNTech COVID-19 vaccine for emergency use, as of December 2020.
The objective was to summarize the repurposed/investigational drugs, their mechanism of action, and rationale for their use in COVID-19 treatment. The article also aimed to summarize the vaccine trials that are currently undergoing across the globe.
In order to find the content for review, studies defining COVID-19 chronology, repurposed drugs along with their mode of action and potential vaccine trials were studied and summarized.
The article summarizes potential therapeutic candidates (repurposed and investigational agents) for SARS-CoV-2, their possible mechanism of action and discussion related to their involvement in recent clinical trials. Innovative vaccine platform technologies are also highlighted that are recently being used in the vaccine production pipeline.
2019 年新型冠状病毒病（COVID-19）于 2019 年 12 月在中国武汉出现，随后迅速在全球范围内传播。世界卫生组织（WHO）、疾病控制与预防中心（CDC）和食品和药物管理局（FDA）的记录证实，没有任何药物被证明对预防或治疗 SARS-CoV-2 完全有效。许多已被重新利用的、正在研究的药物和疫苗候选物的临床试验正在进行中。BioNTech 和辉瑞公司、Moderna、加马列亚研究所和牛津大学（与阿斯利康合作）于 2020 年 11 月宣布了疫苗试验的 3 期中期分析的积极结果。截至 2020 年 12 月，已有 12 个国家批准辉瑞-BioNTech COVID-19 疫苗紧急使用。
总结已被重新利用/正在研究的药物、它们的作用机制以及在 COVID-19 治疗中使用它们的原理。本文还旨在总结目前正在全球范围内进行的疫苗试验。
为了找到综述的内容，研究了定义 COVID-19 时间进程的研究、重新利用的药物及其作用机制和潜在疫苗试验，并进行了总结。
本文总结了 SARS-CoV-2 的潜在治疗候选物（重新利用和研究药物）、它们可能的作用机制，以及讨论它们在最近临床试验中的参与情况。还强调了最近用于疫苗生产管道的创新疫苗平台技术。
